CytomX Therapeutics Net Income 2014-2021 | CTMX

CytomX Therapeutics net income from 2014 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
CytomX Therapeutics Annual Net Income
(Millions of US $)
2020 $-33
2019 $-102
2018 $-85
2017 $-43
2016 $-59
2015 $-42
2014 $-35
2013 $-19
CytomX Therapeutics Quarterly Net Income
(Millions of US $)
2021-06-30 $-19
2021-03-31 $-16
2020-12-31 $-15
2020-09-30 $-15
2020-06-30 $-16
2020-03-31 $12
2019-12-31 $-35
2019-09-30 $-24
2019-06-30 $-29
2019-03-31 $-14
2018-12-31 $-32
2018-09-30 $-23
2018-06-30 $-13
2018-03-31 $-15
2017-12-31 $1
2017-09-30 $-10
2017-06-30 $-25
2017-03-31 $-8
2016-12-31 $-14
2016-09-30 $-15
2016-06-30 $-14
2016-03-31 $-16
2015-12-31 $-12
2015-09-30 $-15
2015-06-30 $-8
2015-03-31 $-8
2014-12-31
2014-09-30 $-5
2013-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.330B $0.100B
CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.038B 8.59
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.127B 20.54
Biohaven Pharmaceutical Holding (BHVN) United States $8.605B 0.00
Emergent Biosolutions (EBS) United States $2.673B 6.45
Arcus Biosciences (RCUS) United States $2.441B 0.00
Myovant Sciences (MYOV) United Kingdom $1.860B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.754B 0.00
Zymeworks (ZYME) Canada $1.075B 0.00
Ambrx Biopharma (AMAM) United States $0.524B 0.00
SQZ Biotechnologies (SQZ) United States $0.335B 0.00
Enzo Biochem (ENZ) United States $0.158B 15.48